0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Orphan Drugs Market Outlook 2022
Published Date: July 2020
|
Report Code: QYRE-Auto-29S2943
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Orphan Drugs Market Insights and Forecast to 2026

Global Orphan Drugs Market Outlook 2022

Code: QYRE-Auto-29S2943
Report
July 2020
127 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures

Orphan Drugs Market Statistics 2027

The global Orphan Drugs market size is projected to reach US$ 241610 million by 2027, from US$ 122720 million in 2020, at a CAGR of 9.7% during 2021-2027. Government officials in a number of countries around the world are pushing for more research and marketing of these treatments, as well as market exclusivity for orphan drugs. As a result, the orphan drug market is expected to grow.

The orphan medicine market has become increasingly lucrative for a variety of reasons. Because orphan medications have smaller trial sizes than more common diseases with larger patient populations, clinical trials for orphan medications are significantly less expensive than for other diseases. Because of their small clinical trials and lack of competition, orphan drugs have an advantage in regulatory evaluation. Furthermore, the market is expected to grow significantly as the number of medications developed for rare blood illnesses and diseases previously thought to be incurable rises.

Orphan Drugs Market

Trends Influencing The Global Orphan Drugs Market   

According to the European Organization for Rare Diseases, an orphan drug is a pharmaceutical product used for the diagnosis, prevention, and treatment of various rare disorders or diseases. These diseases differ from others in that they have a very low prevalence rate compared to other diseases, and thus are only purchased by a small percentage of the population. On the other hand, governments in a number of countries around the world are pushing for the development and commercialization of these drugs. This, in turn, is expected to propel the orphan drug market forward.

Increasing R&D efforts to propel the global orphan drug market forward. One of the major driving factors prevailing in the global market is increased R&D investments by major companies for orphan drug development of unique product offerings. As public awareness of rare diseases has grown, a number of clinical-stage biopharmaceutical startups and established market players have built strong pipeline prospects for orphan medications in various stages of development. This growing interest in rare condition treatments is due to the fact that, in contrast to traditional pharmaceutical portfolios, rare disorders are far more likely to see significant pharmacological breakthroughs leading to blockbuster drug development.

Orphan Drugs Market Share Analysis

North America is expected to be the most profitable region. The increasing occurrence of uncommon illnesses is driving this region's market growth over the forecast period.

Oncology is expected to be the most profitable segment based on type. The dominance can be attributed to the presence of multiple oncology treatments in major companies' product development pipelines, as well as a large number of orphan cancer drugs.

The hospital pharmacy segment is expected to be the most profitable, based on application. The main reason for this dominance is that a large number of medications require intravenous administration by skilled healthcare workers in hospitals.

Orphan Drugs Market Segmentation

Key segments including type, and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2016-2021) and forecast period (2022-2027).

Orphan Drugs Market By Type

  • Oncology
  • Gastrointestinal
  • Pulmonary
  • Neurology
  • Hematology
  • Cardio-vascular
  • Metabolic Disorders
  • Endocrinology
  • Infectious Diseases
  • Others

Orphan Drugs Market By Application

  • Hospital Pharmacies
  • Retail pharmacies
  • Others

Orphan Drugs Market Regional Outook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2016-2027. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region. North America, Europe, China and Japan are the major regions studied in the research report.

Orphan Drugs Market Competitive Landscape

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2016-2021. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Orphan Drugs Market By Company

  • Novartis
  • Bristol-Myers Squibb Company
  • Celgene
  • F. Hoffmann-La Roche
  • Pfizer
  • Sanofi
  • Alexion Pharmaceuticals
  • Eli Lilly and Company
  • Novo Nordisk
  • AstraZeneca
  • Eisai
  • Daiichi Sankyo Company
  • Bayer
  • GlaxoSmithKline
  • Merck & Co
  • Johnson & Johnson
  • Biogen
  • Takeda
  • Amgen

Scope of the Orphan Drugs Market Report

Report Metric

Details

Report Name

Orphan Drugs Market 

The market size in 2020

USD 122720 Million

The revenue forecast in 2027

USD 241610 Million

Growth Rate

Compound Annual Growth Rate (CAGR) of 9.7% from 2021 to 2027

Market size available for years

2021-2027

Forecast units

Value (USD)

Segments covered

By Component, By Process, By Type, Application and Region

Report coverage

Revenue & volume forecast, company share, competitive landscape, growth factors, and trends

Geographic regions covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Frequently Asked Questions About This Report

1.How Big is the a Orphan Drugs Market?

Ans. The global Orphan Drugs market size is projected to reach US$ 241610 million by 2027, from US$ 122720 million in 2020.

2. What is the Orphan Drugs Market Growth?

Ans. The global Orphan Drugs market is expected to grow at a compound annual growth rate of 9.7% from 2021 to 2027.

3. Who are the major key players in Ophan Drugs Market?

Ans. Some of the key players are Pfizer, Sanofi, AstraZeneca, Eisai, Daiichi Sankyo Company, Bayer, GlaxoSmithKline, Merck & Co, Johnson & Johnson, Biogen, Takeda, Amgen & Others.

Table of Contents

 

1 Orphan Drugs Market Overview

    1.1 Product Overview and Scope of Orphan Drugs

    1.2 Orphan Drugs Segment by Type

        1.2.1 Global Orphan Drugs Sales Growth Rate Comparison by Type (2021-2027)

        1.2.2 Oncology

        1.2.3 Gastrointestinal

        1.2.4 Pulmonary

        1.2.5 Neurology

        1.2.6 Hematology

        1.2.7 Cardio-vascular

        1.2.8 Metabolic Disorders

        1.2.9 Endocrinology

        1.2.10 Infectious Diseases

        1.2.11 Others

    1.3 Orphan Drugs Segment by Application

        1.3.1 Global Orphan Drugs Sales Comparison by Application: (2021-2027)

        1.3.2 Hospital Pharmacies

        1.3.3 Retail pharmacies

        1.3.4 Others

    1.4 Global Orphan Drugs Market Size Estimates and Forecasts

        1.4.1 Global Orphan Drugs Revenue 2016-2027

        1.4.2 Global Orphan Drugs Sales 2016-2027

        1.4.3 Orphan Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

 

2 Orphan Drugs Market Competition by Manufacturers

    2.1 Global Orphan Drugs Sales Market Share by Manufacturers (2016-2021)

    2.2 Global Orphan Drugs Revenue Market Share by Manufacturers (2016-2021)

    2.3 Global Orphan Drugs Average Price by Manufacturers (2016-2021)

    2.4 Manufacturers Orphan Drugs Manufacturing Sites, Area Served, Product Type

    2.5 Orphan Drugs Market Competitive Situation and Trends

        2.5.1 Orphan Drugs Market Concentration Rate

        2.5.2 The Global Top 5 and Top 10 Largest Orphan Drugs Players Market Share by Revenue

        2.5.3 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

 

3 Orphan Drugs Retrospective Market Scenario by Region

    3.1 Global Orphan Drugs Retrospective Market Scenario in Sales by Region: 2016-2021

    3.2 Global Orphan Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021

    3.3 North America Orphan Drugs Market Facts & Figures by Country

        3.3.1 North America Orphan Drugs Sales by Country

        3.3.2 North America Orphan Drugs Revenue by Country

        3.3.3 U.S.

        3.3.4 Canada

    3.4 Europe Orphan Drugs Market Facts & Figures by Country

        3.4.1 Europe Orphan Drugs Sales by Country

        3.4.2 Europe Orphan Drugs Revenue by Country

        3.4.3 Germany

        3.4.4 France

        3.4.5 U.K.

        3.4.6 Italy

        3.4.7 Russia

    3.5 Asia Pacific Orphan Drugs Market Facts & Figures by Region

        3.5.1 Asia Pacific Orphan Drugs Sales by Region

        3.5.2 Asia Pacific Orphan Drugs Revenue by Region

        3.5.3 China

        3.5.4 Japan

        3.5.5 South Korea

        3.5.6 India

        3.5.7 Australia

        3.5.8 Taiwan

        3.5.9 Indonesia

        3.5.10 Thailand

        3.5.11 Malaysia

        3.5.12 Philippines

        3.5.13 Vietnam

    3.6 Latin America Orphan Drugs Market Facts & Figures by Country

        3.6.1 Latin America Orphan Drugs Sales by Country

        3.6.2 Latin America Orphan Drugs Revenue by Country

        3.6.3 Mexico

        3.6.4 Brazil

        3.6.5 Argentina

    3.7 Middle East and Africa Orphan Drugs Market Facts & Figures by Country

        3.7.1 Middle East and Africa Orphan Drugs Sales by Country

        3.7.2 Middle East and Africa Orphan Drugs Revenue by Country

        3.7.3 Turkey

        3.7.4 Saudi Arabia

        3.7.5 U.A.E

4 Global Orphan Drugs Historic Market Analysis by Type

    4.1 Global Orphan Drugs Sales Market Share by Type (2016-2021)

    4.2 Global Orphan Drugs Revenue Market Share by Type (2016-2021)

    4.3 Global Orphan Drugs Price by Type (2016-2021)

 

5 Global Orphan Drugs Historic Market Analysis by Application

    5.1 Global Orphan Drugs Sales Market Share by Application (2016-2021)

    5.2 Global Orphan Drugs Revenue Market Share by Application (2016-2021)

    5.3 Global Orphan Drugs Price by Application (2016-2021)

 

6 Key Companies Profiled

    6.1 Novartis

        6.1.1 Novartis Corporation Information

        6.1.2 Novartis Description and Business Overview

        6.1.3 Novartis Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.1.4 Novartis Orphan Drugs Product Portfolio

        6.1.5 Novartis Recent Developments/Updates

    6.2 Bristol-Myers Squibb Company

        6.2.1 Bristol-Myers Squibb Company Corporation Information

        6.2.2 Bristol-Myers Squibb Company Description and Business Overview

        6.2.3 Bristol-Myers Squibb Company Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.2.4 Bristol-Myers Squibb Company Orphan Drugs Product Portfolio

        6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates

    6.3 Celgene

        6.3.1 Celgene Corporation Information

        6.3.2 Celgene Description and Business Overview

        6.3.3 Celgene Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.3.4 Celgene Orphan Drugs Product Portfolio

        6.3.5 Celgene Recent Developments/Updates

    6.4 F. Hoffmann-La Roche

        6.4.1 F. Hoffmann-La Roche Corporation Information

        6.4.2 F. Hoffmann-La Roche Description and Business Overview

        6.4.3 F. Hoffmann-La Roche Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.4.4 F. Hoffmann-La Roche Orphan Drugs Product Portfolio

        6.4.5 F. Hoffmann-La Roche Recent Developments/Updates

    6.5 Pfizer

        6.5.1 Pfizer Corporation Information

        6.5.2 Pfizer Description and Business Overview

        6.5.3 Pfizer Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.5.4 Pfizer Orphan Drugs Product Portfolio

        6.5.5 Pfizer Recent Developments/Updates

    6.6 Sanofi

        6.6.1 Sanofi Corporation Information

        6.6.2 Sanofi Description and Business Overview

        6.6.3 Sanofi Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.6.4 Sanofi Orphan Drugs Product Portfolio

        6.6.5 Sanofi Recent Developments/Updates

    6.7 Alexion Pharmaceuticals

        6.6.1 Alexion Pharmaceuticals Corporation Information

        6.6.2 Alexion Pharmaceuticals Description and Business Overview

        6.6.3 Alexion Pharmaceuticals Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.4.4 Alexion Pharmaceuticals Orphan Drugs Product Portfolio

        6.7.5 Alexion Pharmaceuticals Recent Developments/Updates

    6.8 Eli Lilly and Company

        6.8.1 Eli Lilly and Company Corporation Information

        6.8.2 Eli Lilly and Company Description and Business Overview

        6.8.3 Eli Lilly and Company Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.8.4 Eli Lilly and Company Orphan Drugs Product Portfolio

        6.8.5 Eli Lilly and Company Recent Developments/Updates

    6.9 Novo Nordisk

        6.9.1 Novo Nordisk Corporation Information

        6.9.2 Novo Nordisk Description and Business Overview

        6.9.3 Novo Nordisk Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.9.4 Novo Nordisk Orphan Drugs Product Portfolio

        6.9.5 Novo Nordisk Recent Developments/Updates

    6.10 AstraZeneca

        6.10.1 AstraZeneca Corporation Information

        6.10.2 AstraZeneca Description and Business Overview

        6.10.3 AstraZeneca Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.10.4 AstraZeneca Orphan Drugs Product Portfolio

        6.10.5 AstraZeneca Recent Developments/Updates

    6.11 Eisai

        6.11.1 Eisai Corporation Information

        6.11.2 Eisai Orphan Drugs Description and Business Overview

        6.11.3 Eisai Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.11.4 Eisai Orphan Drugs Product Portfolio

        6.11.5 Eisai Recent Developments/Updates

    6.12 Daiichi Sankyo Company

        6.12.1 Daiichi Sankyo Company Corporation Information

        6.12.2 Daiichi Sankyo Company Orphan Drugs Description and Business Overview

        6.12.3 Daiichi Sankyo Company Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.12.4 Daiichi Sankyo Company Orphan Drugs Product Portfolio

        6.12.5 Daiichi Sankyo Company Recent Developments/Updates

    6.13 Bayer

        6.13.1 Bayer Corporation Information

        6.13.2 Bayer Orphan Drugs Description and Business Overview

        6.13.3 Bayer Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.13.4 Bayer Orphan Drugs Product Portfolio

        6.13.5 Bayer Recent Developments/Updates

    6.14 GlaxoSmithKline

        6.14.1 GlaxoSmithKline Corporation Information

        6.14.2 GlaxoSmithKline Orphan Drugs Description and Business Overview

        6.14.3 GlaxoSmithKline Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.14.4 GlaxoSmithKline Orphan Drugs Product Portfolio

        6.14.5 GlaxoSmithKline Recent Developments/Updates

    6.15 Merck & Co

        6.15.1 Merck & Co Corporation Information

        6.15.2 Merck & Co Orphan Drugs Description and Business Overview

        6.15.3 Merck & Co Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.15.4 Merck & Co Orphan Drugs Product Portfolio

        6.15.5 Merck & Co Recent Developments/Updates

    6.16 Johnson & Johnson

        6.16.1 Johnson & Johnson Corporation Information

        6.16.2 Johnson & Johnson Orphan Drugs Description and Business Overview

        6.16.3 Johnson & Johnson Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.16.4 Johnson & Johnson Orphan Drugs Product Portfolio

        6.16.5 Johnson & Johnson Recent Developments/Updates

    6.17 Biogen

        6.17.1 Biogen Corporation Information

        6.17.2 Biogen Orphan Drugs Description and Business Overview

        6.17.3 Biogen Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.17.4 Biogen Orphan Drugs Product Portfolio

        6.17.5 Biogen Recent Developments/Updates

    6.18 Takeda

        6.18.1 Takeda Corporation Information

        6.18.2 Takeda Orphan Drugs Description and Business Overview

        6.18.3 Takeda Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.18.4 Takeda Orphan Drugs Product Portfolio

        6.18.5 Takeda Recent Developments/Updates

    6.19 Amgen

        6.19.1 Amgen Corporation Information

        6.19.2 Amgen Orphan Drugs Description and Business Overview

        6.19.3 Amgen Orphan Drugs Sales, Revenue and Gross Margin (2016-2021)

        6.19.4 Amgen Orphan Drugs Product Portfolio

        6.19.5 Amgen Recent Developments/Updates

 

7 Orphan Drugs Manufacturing Cost Analysis

    7.1 Orphan Drugs Key Raw Materials Analysis

       7.1.1 Key Raw Materials

       7.1.2 Key Suppliers of Raw Materials

    7.2 Proportion of Manufacturing Cost Structure

    7.3 Manufacturing Process Analysis of Orphan Drugs

    7.4 Orphan Drugs Industrial Chain Analysis

 

8 Marketing Channel, Distributors and Customers

    8.1 Marketing Channel

    8.2 Orphan Drugs Distributors List

    8.3 Orphan Drugs Customers

 

9 Orphan Drugs Market Dynamics

    9.1 Orphan Drugs Industry Trends

    9.2 Orphan Drugs Growth Drivers

    9.3 Orphan Drugs Market Challenges

    9.4 Orphan Drugs Market Restraints

 

10 Global Market Forecast

    10.1 Orphan Drugs Market Estimates and Projections by Type

        10.1.1 Global Forecasted Sales of Orphan Drugs by Type (2022-2027)

        10.1.2 Global Forecasted Revenue of Orphan Drugs by Type (2022-2027)

    10.2 Orphan Drugs Market Estimates and Projections by Application

        10.2.1 Global Forecasted Sales of Orphan Drugs by Application (2022-2027)

        10.2.2 Global Forecasted Revenue of Orphan Drugs by Application (2022-2027)

    10.3 Orphan Drugs Market Estimates and Projections by Region

        10.3.1 Global Forecasted Sales of Orphan Drugs by Region (2022-2027)

        10.3.2 Global Forecasted Revenue of Orphan Drugs by Region (2022-2027)

 

11 Research Finding and Conclusion

 

12 Methodology and Data Source

    12.1 Methodology/Research Approach

        12.1.1 Research Programs/Design

        12.1.2 Market Size Estimation

        12.1.3 Market Breakdown and Data Triangulation

    12.2 Data Source

        12.2.1 Secondary Sources

        12.2.2 Primary Sources

    12.3 Author List

    12.4 Disclaimer

List of Tables

Table 1. Global Orphan Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027)

Table 2. Global Orphan Drugs Sales (K Units) Comparison by Application (2021-2027)

Table 3. Global Orphan Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)

Table 4. Key Manufacturers Orphan Drugs Covered in This Study

Table 5. Global Orphan Drugs Sales (K Units) of Key Manufacturers (2016-2021)

Table 6. Global Orphan Drugs Sales Market Share by Manufacturers (2016-2021)

Table 7. Global Orphan Drugs Revenue (US$ Million) by Manufacturers (2016-2021)

Table 8. Global Orphan Drugs Revenue Share by Manufacturers (2016-2021)

Table 9. Global Market Orphan Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021)

Table 10. Manufacturers Orphan Drugs Manufacturing Sites and Area Served

Table 11. Manufacturers Orphan Drugs Product Type

Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 13. Global Orphan Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Orphan Drugs as of 2020)

Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 15. Global Orphan Drugs Sales by Region (2016-2021) & (K Units)

Table 16. Global Orphan Drugs Sales Market Share by Region (2016-2021)

Table 17. Global Orphan Drugs Revenue by Region (2016-2021) & (US$ Million)

Table 18. North America Orphan Drugs Sales by Country (2016-2021) & (K Units)

Table 19. North America Orphan Drugs Sales Market Share by Country (2016-2021)

Table 20. North America Orphan Drugs Revenue by Country (2016-2021) & (US$ Million)

Table 21. North America Orphan Drugs Revenue Market Share by Country (2016-2021)

Table 22. Europe Orphan Drugs Sales by Country (2016-2021) & (K Units)

Table 23. Europe Orphan Drugs Sales Market Share by Country (2016-2021)

Table 24. Europe Orphan Drugs Revenue by Country (2016-2021) & (US$ Million)

Table 25. Europe Orphan Drugs Revenue Market Share by Country (2016-2021)

Table 26. Asia Pacific Orphan Drugs Sales by Region (2016-2021) & (K Units)

Table 27. Asia Pacific Orphan Drugs Sales Market Share by Region (2016-2021)

Table 28. Asia Pacific Orphan Drugs Revenue by Region (2016-2021) & (US$ Million)

Table 29. Asia Pacific Orphan Drugs Revenue Market Share by Region (2016-2021)

Table 30. Latin America Orphan Drugs Sales by Country (2016-2021) & (K Units)

Table 31. Latin America Orphan Drugs Sales Market Share by Country (2016-2021)

Table 32. Latin America Orphan Drugs Revenue by Country (2016-2021) & (US$ Million)

Table 33. Latin America Orphan Drugs Revenue Market Share by Country (2016-2021)

Table 34. Middle East and Africa Orphan Drugs Sales by Country (2016-2021) & (K Units)

Table 35. Middle East and Africa Orphan Drugs Sales Market Share by Country (2016-2021)

Table 36. Middle East and Africa Orphan Drugs Revenue by Country (2016-2021) & (US$ Million)

Table 37. Middle East and Africa Orphan Drugs Revenue Market Share by Country (2016-2021)

Table 38. Global Orphan Drugs Sales (K Units) by Type (2016-2021)

Table 39. Global Orphan Drugs Sales Market Share by Type (2016-2021)

Table 40. Global Orphan Drugs Revenue (Million US$) by Type (2016-2021)

Table 41. Global Orphan Drugs Revenue Share by Type (2016-2021)

Table 42. Global Orphan Drugs Price (USD/Unit) by Type (2016-2021)

Table 43. Global Orphan Drugs Sales (K Units) by Application (2016-2021)

Table 44. Global Orphan Drugs Sales Market Share by Application (2016-2021)

Table 45. Global Orphan Drugs Revenue (Million US$) by Application (2016-2021)

Table 46. Global Orphan Drugs Revenue Share by Application (2016-2021)

Table 47. Global Orphan Drugs Price (USD/Unit) by Application (2016-2021)

Table 48. Novartis Corporation Information

Table 49. Novartis Description and Business Overview

Table 50. Novartis Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 51. Novartis Orphan Drugs Product

Table 52. Novartis Recent Developments/Updates

Table 53. Bristol-Myers Squibb Company Corporation Information

Table 54. Bristol-Myers Squibb Company Description and Business Overview

Table 55. Bristol-Myers Squibb Company Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 56. Bristol-Myers Squibb Company Orphan Drugs Product

Table 57. Bristol-Myers Squibb Company Recent Developments/Updates

Table 58. Celgene Corporation Information

Table 59. Celgene Description and Business Overview

Table 60. Celgene Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 61. Celgene Orphan Drugs Product

Table 62. Celgene Recent Developments/Updates

Table 63. F. Hoffmann-La Roche Corporation Information

Table 64. F. Hoffmann-La Roche Description and Business Overview

Table 65. F. Hoffmann-La Roche Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 66. F. Hoffmann-La Roche Orphan Drugs Product

Table 67. F. Hoffmann-La Roche Recent Developments/Updates

Table 68. Pfizer Corporation Information

Table 69. Pfizer Description and Business Overview

Table 70. Pfizer Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 71. Pfizer Orphan Drugs Product

Table 72. Pfizer Recent Developments/Updates

Table 73. Sanofi Corporation Information

Table 74. Sanofi Description and Business Overview

Table 75. Sanofi Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 76. Sanofi Orphan Drugs Product

Table 77. Sanofi Recent Developments/Updates

Table 78. Alexion Pharmaceuticals Corporation Information

Table 79. Alexion Pharmaceuticals Description and Business Overview

Table 80. Alexion Pharmaceuticals Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 81. Alexion Pharmaceuticals Orphan Drugs Product

Table 82. Alexion Pharmaceuticals Recent Developments/Updates

Table 83. Eli Lilly and Company Corporation Information

Table 84. Eli Lilly and Company Description and Business Overview

Table 85. Eli Lilly and Company Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 86. Eli Lilly and Company Orphan Drugs Product

Table 87. Eli Lilly and Company Recent Developments/Updates

Table 88. Novo Nordisk Corporation Information

Table 89. Novo Nordisk Description and Business Overview

Table 90. Novo Nordisk Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 91. Novo Nordisk Orphan Drugs Product

Table 92. Novo Nordisk Recent Developments/Updates

Table 93. AstraZeneca Corporation Information

Table 94. AstraZeneca Description and Business Overview

Table 95. AstraZeneca Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 96. AstraZeneca Orphan Drugs Product

Table 97. AstraZeneca Recent Developments/Updates

Table 98. Eisai Corporation Information

Table 99. Eisai Description and Business Overview

Table 100. Eisai Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 101. Eisai Orphan Drugs Product

Table 102. Eisai Recent Developments/Updates

Table 103. Daiichi Sankyo Company Corporation Information

Table 104. Daiichi Sankyo Company Description and Business Overview

Table 105. Daiichi Sankyo Company Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 106. Daiichi Sankyo Company Orphan Drugs Product

Table 107. Daiichi Sankyo Company Recent Developments/Updates

Table 108. Bayer Corporation Information

Table 109. Bayer Description and Business Overview

Table 110. Bayer Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 111. Bayer Orphan Drugs Product

Table 112. Bayer Recent Developments/Updates

Table 113. GlaxoSmithKline Corporation Information

Table 114. GlaxoSmithKline Description and Business Overview

Table 115. GlaxoSmithKline Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 116. GlaxoSmithKline Orphan Drugs Product

Table 117. GlaxoSmithKline Recent Developments/Updates

Table 118. Merck & Co Corporation Information

Table 119. Merck & Co Description and Business Overview

Table 120. Merck & Co Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 121. Merck & Co Orphan Drugs Product

Table 122. Merck & Co Recent Developments/Updates

Table 123. Johnson & Johnson Corporation Information

Table 124. Johnson & Johnson Description and Business Overview

Table 125. Johnson & Johnson Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 126. Johnson & Johnson Orphan Drugs Product

Table 127. Johnson & Johnson Recent Developments/Updates

Table 128. Biogen Corporation Information

Table 129. Biogen Description and Business Overview

Table 130. Biogen Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 131. Biogen Orphan Drugs Product

Table 132. Biogen Recent Developments/Updates

Table 133. Takeda Corporation Information

Table 134. Takeda Description and Business Overview

Table 135. Takeda Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 136. Takeda Orphan Drugs Product

Table 137. Takeda Recent Developments/Updates

Table 138. Amgen Corporation Information

Table 139. Amgen Description and Business Overview

Table 140. Amgen Orphan Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)

Table 141. Amgen Orphan Drugs Product

Table 142. Amgen Recent Developments/Updates

Table 143. Production Base and Market Concentration Rate of Raw Material

Table 144. Key Suppliers of Raw Materials

Table 145. Orphan Drugs Distributors List

Table 146. Orphan Drugs Customers List

Table 147. Orphan Drugs Market Trends

Table 148. Orphan Drugs Growth Drivers

Table 149. Orphan Drugs Market Challenges

Table 150. Orphan Drugs Market Restraints

Table 151. Global Orphan Drugs Sales Forecast by Type (2022-2027) & (K Units)

Table 152. Global Orphan Drugs Sales Market Share Forecast by Type (2022-2027)

Table 153. Global Orphan Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)

Table 154. Global Orphan Drugs Revenue Market Share Forecast by Type (2022-2027)

Table 155. Global Orphan Drugs Sales Forecast by Application (2022-2027) & (K Units)

Table 156. Global Orphan Drugs Sales Market Share Forecast by Application (2022-2027)

Table 157. Global Orphan Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)

Table 158. Global Orphan Drugs Revenue Market Share Forecast by Application (2022-2027)

Table 159. Global Orphan Drugs Sales Forecast by Region (2022-2027) & (K Units)

Table 160. Global Orphan Drugs Sales Market Share Forecast by Region (2022-2027)

Table 161. Global Orphan Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)

Table 162. Global Orphan Drugs Revenue Market Share Forecast by Region (2022-2027)

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Orphan Drugs

Figure 2. Global Orphan Drugs Market Share by Type in 2020 & 2027

Figure 3. Oncology Product Picture

Figure 4. Gastrointestinal Product Picture

Figure 5. Pulmonary Product Picture

Figure 6. Neurology Product Picture

Figure 7. Hematology Product Picture

Figure 8. Cardio-vascular Product Picture

Figure 9. Metabolic Disorders Product Picture

Figure 10. Endocrinology Product Picture

Figure 11. Infectious Diseases Product Picture

Figure 12. Others Product Picture

Figure 13. Global Orphan Drugs Market Share by Application in 2020 & 2027

Figure 14. Hospital Pharmacies

Figure 15. Retail pharmacies

Figure 16. Others

Figure 17. Global Orphan Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027

Figure 18. Global Orphan Drugs Market Size 2016-2027 (US$ Million)

Figure 19. Global Orphan Drugs Sales 2016-2027 (K Units)

Figure 20. Global Orphan Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027

Figure 21. Orphan Drugs Sales Share by Manufacturers in 2020

Figure 22. Global Orphan Drugs Revenue Share by Manufacturers in 2020

Figure 23. The Global 5 and 10 Largest Orphan Drugs Players: Market Share by Revenue in 2020

Figure 24. Orphan Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021

Figure 25. Global Orphan Drugs Sales Market Share by Region (2016-2021)

Figure 26. Global Orphan Drugs Sales Market Share by Region in 2020

Figure 27. Global Orphan Drugs Revenue Market Share by Region (2016-2021)

Figure 28. Global Orphan Drugs Revenue Market Share by Region in 2020

Figure 29. U.S. Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 30. Canada Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 31. Germany Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 32. France Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 33. U.K. Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 34. Italy Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 35. Russia Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 36. China Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 37. Japan Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 38. South Korea Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 39. India Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 40. Australia Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 41. Taiwan Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 42. Indonesia Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 43. Thailand Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 44. Malaysia Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 45. Philippines Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 46. Vietnam Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 47. Mexico Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 48. Brazil Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 49. Argentina Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 50. Turkey Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 51. Saudi Arabia Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 52. U.A.E Orphan Drugs Revenue Growth Rate (2016-2021) (US$ Million)

Figure 53. Sales Market Share of Orphan Drugs by Type (2016-2021)

Figure 54. Sales Market Share of Orphan Drugs by Application (2016-2021)

Figure 55. Sales Market Share of Orphan Drugs by Application in 2020

Figure 56. Revenue Share of Orphan Drugs by Application (2016-2021)

Figure 57. Revenue Share of Orphan Drugs by Application in 2020

Figure 58. Manufacturing Cost Structure of Orphan Drugs

Figure 59. Manufacturing Process Analysis of Orphan Drugs

Figure 60. Orphan Drugs Industrial Chain Analysis

Figure 61. Channels of Distribution

Figure 62. Distributors Profiles

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

 

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$2900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

Global Manual Capsule Filling Machine Market Insights Forecast to 2028
Global Manual Capsule Filling Machine Market Insights, Forecast to 2028

To form a capsule the powder or formulation containing active ingredients and the mixtures of active ingredients with combinations of different excipient materials are filled with the help of filling rings into the body of the capsule from the powder hopper and then close the body of the capsule with the cap by the help of second filling ring.Market Analysis and Insights Global Manual Capsule Filling Machine MarketDue to the COVID19 pandemic the global Manual Capsule Filling Machine market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review p. category - Machinery Equipment

120 Pages
Type: Report
Code: QYRE-Auto-38G9544
Mon Feb 28 00:00:00 UTC 2022

Add to Cart

Global Injectable Hyaluronic Acid Market Insights Forecast to 2028
Global Injectable Hyaluronic Acid Market Insights, Forecast to 2028

Market Analysis and Insights Global Injectable Hyaluronic Acid MarketDue to the COVID19 pandemic the global Injectable Hyaluronic Acid market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-6W1477
Mon Feb 28 00:00:00 UTC 2022

Add to Cart

Global Crosslinking Reagents Market Insights Forecast to 2028
Global Crosslinking Reagents Market Insights, Forecast to 2028

Market Analysis and Insights Global Crosslinking Reagents MarketDue to the COVID19 pandemic the global Crosslinking Reagents market size is estimated to be worth US 12110 million in 2022 and is forecast to a readjusted size of US 14740 million by 2028 with a CAGR of 3.3 during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-38F9548
Mon Feb 28 00:00:00 UTC 2022

Add to Cart

Global Parenteral Nutrition Solutions Market Insights Forecast to 2028
Global Parenteral Nutrition Solutions Market Insights, Forecast to 2028

Market Analysis and Insights Global Parenteral Nutrition Solutions MarketThe global Parenteral Nutrition Solutions market size is projected to reach US million by 2028 from US million in 2021 at a CAGR of during 20222028.Fully considering the economic change by this health crisis Large Volume Parenteral LVP accounting for of the Parenteral Nutrition Solutions global market in 2021 is projected to value US million by 2028 growing at a revised CAGR in the postCOVID19 period.

120 Pages
Type: Report
Code: QYRE-Auto-19A6022
Mon Feb 28 00:00:00 UTC 2022

Add to Cart